Over 55,000 people are diagnosed with pancreatic cancer every year. And about 95 percent of people who are diagnosed with pancreatic cancer will lose their lives from it. Pancreatic…
According to a story from globenewswire.com, the company Progenic Pharmaceuticals recently reported the the U.S. Food and Drug Administration has recently approved the company's product iobenguane I 131 (AZEDRA). This…
According to a story from bioengineer.org, a group of scientists working at the Columbia University Irving Medical Center (CUIMC) have managed to develop a computational model that could potentially make highly…
According to a story from news-medical.net, the results of a recent research trial demonstrate that the radiation therapy drug AZEDRA (ultratrace iobenguane I131) is an effective and safe treatment option…
In a press release, CURE Media Group announced the development of a 13-part series on carcinoid syndrome. A series of discussions involving both doctors and patients educating patients, caregivers and…
According to a story from biospace.com, a research team from the National Cancer Institute was able to successfully deliver an experimental nanomedicine to mice that had rare cancers such as…
Pancreatic CancerWhat is pancreatic cancer?Pancreatic cancer occurs in the pancreas, an organ that lies behind the lower part of the stomach. The pancreas releases enzymes that help you digest food,…
Von Hippel-Lindau (VHL) SyndromeWhat is von Hippel-Lindau (VHL) syndrome?Von Hippel-Lindau syndrome, or VHL, is a rare inherited disorder that is characterized by the formation of tumors and cysts in different…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
